PDL BioPharma, Inc. Notes Payable, Fair Value Disclosure
PDL BioPharma, Inc. had Notes Payable, Fair Value Disclosure of $16.20 million as of 2020-06-30, per its 10-Q filed 2020-08-07.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Financial Instruments, Financial Liabilities, Balance Sheet Groupings
us-gaap:NotesPayableFairValueDisclosure · last filed 2020-11-13
- 2020-06-30: Notes Payable, Fair Value Disclosure $16.20M.
- 2020-03-31: Notes Payable, Fair Value Disclosure $15.90M.
- 2019-12-31: Notes Payable, Fair Value Disclosure $33.90M.
- 2011-12-31: Notes Payable, Fair Value Disclosure $442.83M.
| Period end | Notes Payable, Fair Value Disclosure |
|---|---|
| 2020-06-30 | $16.20M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $15.90M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $33.90M 10-Q · filed 2020-11-13 |
| 2011-12-31 | $442.83M 10-K · filed 2012-02-23 |
| 2011-09-30 | $442.64M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $476.04M 10-Q · filed 2011-07-29 |